Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBIO NASDAQ:FLXN NASDAQ:MDVL NASDAQ:URGN NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBIOFortress Biotech$2.74-2.8%$2.91$1.33▼$4.20$81.52M1.75500,698 shs726,835 shsFLXNFlexion Therapeutics$25.63+0.3%$9.20$4.30▼$13.66$1.29B1.531.18 million shs1,860 shsMDVLMedAvail$3.31$1.31▼$20.89$2.91M0.76261,432 shs245,100 shsURGNUrogen Pharma$16.93-2.1%$18.55$3.42▼$21.71$783.25M11.48 million shs821,636 shsXOMAXOMA Royalty$36.49-2.4%$34.97$18.35▼$39.92$441.16M1.0246,278 shs53,135 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBIOFortress Biotech+3.30%-3.09%-20.56%+46.11%+63.95%FLXNFlexion Therapeutics+0.20%-0.39%+0.04%+2.30%+180.26%MDVLMedAvail0.00%0.00%0.00%0.00%0.00%URGNUrogen Pharma+3.84%-0.23%-4.26%+12.20%+41.03%XOMAXOMA Royalty+1.03%+2.86%-1.24%+42.17%+30.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBIOFortress Biotech$2.74-2.8%$2.91$1.33▼$4.20$81.52M1.75500,698 shs726,835 shsFLXNFlexion Therapeutics$25.63+0.3%$9.20$4.30▼$13.66$1.29B1.531.18 million shs1,860 shsMDVLMedAvail$3.31$1.31▼$20.89$2.91M0.76261,432 shs245,100 shsURGNUrogen Pharma$16.93-2.1%$18.55$3.42▼$21.71$783.25M11.48 million shs821,636 shsXOMAXOMA Royalty$36.49-2.4%$34.97$18.35▼$39.92$441.16M1.0246,278 shs53,135 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBIOFortress Biotech+3.30%-3.09%-20.56%+46.11%+63.95%FLXNFlexion Therapeutics+0.20%-0.39%+0.04%+2.30%+180.26%MDVLMedAvail0.00%0.00%0.00%0.00%0.00%URGNUrogen Pharma+3.84%-0.23%-4.26%+12.20%+41.03%XOMAXOMA Royalty+1.03%+2.86%-1.24%+42.17%+30.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBIOFortress Biotech 2.33Hold$16.50502.19% UpsideFLXNFlexion Therapeutics 0.00N/AN/AN/AMDVLMedAvail 0.00N/AN/AN/AURGNUrogen Pharma 2.67Moderate Buy$32.0089.01% UpsideXOMAXOMA Royalty 2.75Moderate Buy$69.5090.46% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, URGN, FLXN, XOMA, and MDVL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025FBIOFortress BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025URGNUrogen PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025XOMAXOMA RoyaltyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/3/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.009/27/2025FBIOFortress BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025URGNUrogen PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025XOMAXOMA RoyaltyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/10/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/21/2025FBIOFortress BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $17.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.008/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBIOFortress Biotech$57.67M1.41N/AN/A($0.06) per share-45.67FLXNFlexion Therapeutics$85.55M15.08N/AN/A($0.34) per share-75.38MDVLMedAvail$43.33M0.00N/AN/A$13.01 per share0.00URGNUrogen Pharma$94.24M8.31N/AN/A($0.21) per share-80.62XOMAXOMA Royalty$28.49M15.48N/AN/A$6.95 per share5.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/AMDVLMedAvail-$47.62M-$28.72N/AN/AN/A-192.97%-218.10%-103.45%N/AURGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest FBIO, URGN, FLXN, XOMA, and MDVL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025FBIOFortress Biotech-$0.32N/AN/AN/AN/AN/A11/6/2025Q3 2025XOMAXOMA Royalty-$0.02N/AN/AN/A$11.47 millionN/A11/5/2025Q3 2025URGNUrogen Pharma-$0.70N/AN/AN/A$34.09 millionN/A8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBIOFortress BiotechN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AMDVLMedAvailN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBIOFortress Biotech1.341.921.70FLXNFlexion TherapeuticsN/A4.384.05MDVLMedAvailN/AN/AN/AURGNUrogen PharmaN/A4.143.99XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBIOFortress Biotech96.51%FLXNFlexion Therapeutics90.01%MDVLMedAvailN/AURGNUrogen Pharma91.29%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipFBIOFortress Biotech27.90%FLXNFlexion Therapeutics9.13%MDVLMedAvail1.50%URGNUrogen Pharma4.70%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBIOFortress Biotech17029.75 million21.45 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataMDVLMedAvail2791.61 million1.59 millionNo DataURGNUrogen Pharma20046.26 million44.09 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionableFBIO, URGN, FLXN, XOMA, and MDVL HeadlinesRecent News About These CompaniesXOMA Royalty (NASDAQ:XOMA) Shares Pass Above Two Hundred Day Moving Average - Here's WhyOctober 15 at 4:19 AM | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for XOMA Royalty (NASDAQ:XOMA)October 8, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?October 7, 2025 | marketbeat.comXOMA Royalty PFD Update: Going Back To My Original Sell RatingsOctober 3, 2025 | seekingalpha.comXOMA Royalty PFD Update: Going Back To My Original Sell RatingsOctober 3, 2025 | seekingalpha.comXoma extends offer to acquire Lava TherapeuticsOctober 2, 2025 | msn.comLAVA Therapeutics Extends Tender Offer DeadlineOctober 2, 2025 | tipranks.comXOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025October 2, 2025 | quiverquant.comQXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.October 2, 2025 | globenewswire.comQ3 Saw Some of the Highest-Value Biopharma Acquisitions of the Year So FarOctober 1, 2025 | biospace.comBLAVA Therapeutics Cancels Extraordinary General Meeting to Finalize XOMA Royalty Acquisition DetailsSeptember 30, 2025 | quiverquant.comQGoldman Sachs Group Inc. Sells 9,447 Shares of XOMA Royalty Corporation $XOMASeptember 29, 2025 | marketbeat.comEssa Pharma Agrees to Amend Terms to be Acquired by XenoTherapeuticsSeptember 24, 2025 | marketwatch.comESSA Pharma cuts shareholder payout in revised Xeno dealSeptember 24, 2025 | msn.comESSA Pharma Inc. Amends Agreement with XenoTherapeuticsSeptember 24, 2025 | prnewswire.comInsider Selling: XOMA Royalty (NASDAQ:XOMA) CFO Sells 4,330 Shares of StockSeptember 24, 2025 | insidertrades.comMural Oncology plc Publishes Definitive Proxy Statement for Acquisition by XOMA Royalty CorporationSeptember 23, 2025 | quiverquant.comQXOMA Royalty (NASDAQ:XOMA) CFO Sells $155,836.70 in StockSeptember 23, 2025 | marketbeat.comMural Oncology Plc Announces Acquisition by XOMA Royalty CorporationSeptember 23, 2025 | tipranks.comInsider Sale: SVP of $XOMA Sells 15 SharesSeptember 23, 2025 | quiverquant.comQXoma Completes Acquisition of HilleVaxSeptember 23, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, URGN, FLXN, XOMA, and MDVL Company DescriptionsFortress Biotech NASDAQ:FBIO$2.74 -0.08 (-2.84%) Closing price 04:00 PM EasternExtended Trading$2.72 -0.02 (-0.77%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.MedAvail NASDAQ:MDVLMedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.Urogen Pharma NASDAQ:URGN$16.93 -0.36 (-2.08%) Closing price 04:00 PM EasternExtended Trading$17.10 +0.16 (+0.97%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.XOMA Royalty NASDAQ:XOMA$36.49 -0.90 (-2.41%) Closing price 04:00 PM EasternExtended Trading$37.04 +0.55 (+1.51%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
